Replies to post #130933 on Biotech Values

[iandy]

I’m referring to generics in the next few years for Gleevec (a certainty) and Sprycel (a possibility), not to generics for Ponatinib.

I caught the mistake and deleted my post.
Rather than fix the post I went to watch some football.
I am,unfortunately,an Eagles fan.

Can you name many instances of other small biotechs,such as Ariad, that have had two wholly owned compounds that were potentially best in class and approvable in a relatively short period of time?

Harvey's "pumping" might be justified. All indications are pona will get an early approval and 113 might prove efficacious in multiple indications.

I see no reason to believe Harvey is not capable of advancing Ariad to very profitable stand-alone biotech status.
He has done a great job advancing the company this past year.